The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Omiya, R.
Right arrow Articles by Celis, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omiya, R.
Right arrow Articles by Celis, E.
The Journal of Immunology, 2002, 169: 2172-2179.
Copyright © 2002 by The American Association of Immunologists

Inhibition of EBV-Induced Lymphoproliferation by CD4+ T Cells Specific for an MHC Class II Promiscuous Epitope1

Ryusuke Omiya*, Chantal Buteau{dagger}, Hiroya Kobayashi*, Carlos V. Paya{dagger} and Esteban Celis2,*

* Department of Immunology and {dagger} Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905

Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4+ T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid organ transplant patients.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
E. Tassi, F. Gavazzi, L. Albarello, V. Senyukov, R. Longhi, P. Dellabona, C. Doglioni, M. Braga, V. Di Carlo, and M. P. Protti
Carcinoembryonic Antigen-Specific but Not Antiviral CD4+ T Cell Immunity Is Impaired in Pancreatic Carcinoma Patients
J. Immunol., November 1, 2008; 181(9): 6595 - 6603.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, T. Nagato, M. Takahara, K. Sato, S. Kimura, N. Aoki, M. Azumi, M. Tateno, Y. Harabuchi, and E. Celis
Induction of EBV-Latent Membrane Protein 1-Specific MHC Class II-Restricted T-Cell Responses against Natural Killer Lymphoma Cells
Cancer Res., February 1, 2008; 68(3): 901 - 908.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. A. Haigh, X. Lin, H. Jia, E. P. Hui, A. T. C. Chan, A. B. Rickinson, and G. S. Taylor
EBV Latent Membrane Proteins (LMPs) 1 and 2 as Immunotherapeutic Targets: LMP-Specific CD4+ Cytotoxic T Cell Recognition of EBV-Transformed B Cell Lines
J. Immunol., February 1, 2008; 180(3): 1643 - 1654.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Bhaduri-McIntosh, M. J. Rotenberg, B. Gardner, M. Robert, and G. Miller
Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines
Blood, February 1, 2008; 111(3): 1334 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
B. P. O'Neill, S. Vernino, A. Dogan, and C. Giannini
EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil
Neuro-oncol, July 1, 2007; 9(3): 364 - 369.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kobayashi, T. Nagato, K. Sato, N. Aoki, S. Kimura, M. Murakami, H. Iizuka, M. Azumi, H. Kakizaki, M. Tateno, et al.
Recognition of Prostate and Melanoma Tumor Cells by Six-Transmembrane Epithelial Antigen of Prostate-Specific Helper T Lymphocytes in a Human Leukocyte Antigen Class II-Restricted Manner
Cancer Res., June 1, 2007; 67(11): 5498 - 5504.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. S. Taylor, H. M. Long, T. A. Haigh, M. Larsen, J. Brooks, and A. B. Rickinson
A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells
J. Immunol., September 15, 2006; 177(6): 3746 - 3756.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Ngato, K. Sato, N. Aoki, S. Kimura, Y. Tanaka, H. Aizawa, M. Tateno, and E. Celis
In vitro Peptide Immunization of Target Tax Protein Human T-Cell Leukemia Virus Type 1-Specific CD4+ Helper T Lymphocytes.
Clin. Cancer Res., June 15, 2006; 12(12): 3814 - 3822.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. N. Heller, C. Gurer, and C. Munz
Virus-specific CD4+ T cells: ready for direct attack
J. Exp. Med., April 17, 2006; 203(4): 805 - 808.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Landais, X. Saulquin, M. Bonneville, and E. Houssaint
Long-Term MHC Class II Presentation of the EBV Lytic Protein BHRF1 by EBV Latently Infected B Cells following Capture of BHRF1 Antigen
J. Immunol., December 15, 2005; 175(12): 7939 - 7946.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Piriou, K. van Dort, N. M. Nanlohy, M. H. J. van Oers, F. Miedema, and D. van Baarle
Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma
Blood, November 1, 2005; 106(9): 3166 - 3174.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Nagato, K. Oikawa, K. Sato, S. Kimura, N. Aoki, R. Omiya, M. Tateno, and E. Celis
Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP
Clin. Cancer Res., May 15, 2005; 11(10): 3869 - 3878.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. H. Gudgeon, G. S. Taylor, H. M. Long, T. A. Haigh, and A. B. Rickinson
Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity
J. Virol., May 1, 2005; 79(9): 5477 - 5488.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
H. M. Long, T. A. Haigh, N. H. Gudgeon, A. M. Leen, C.-W. Tsang, J. Brooks, E. Landais, E. Houssaint, S. P. Lee, A. B. Rickinson, et al.
CD4+ T-Cell Responses to Epstein-Barr Virus (EBV) Latent-Cycle Antigens and the Recognition of EBV-Transformed Lymphoblastoid Cell Lines
J. Virol., April 15, 2005; 79(8): 4896 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, T. Nagato, M. Yanai, K. Oikawa, K. Sato, S. Kimura, M. Tateno, R. Omiya, and E. Celis
Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein
Clin. Cancer Res., October 15, 2004; 10(20): 7053 - 7062.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
A. H. Undale, P. J. van den Elsen, and E. Celis
Antigen-independent acquisition of MHC class II molecules by human T lymphocytes
Int. Immunol., October 1, 2004; 16(10): 1523 - 1533.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. L. Sparks-Thissen, D. C. Braaten, S. Kreher, S. H. Speck, and H. W. Virgin IV
An Optimized CD4 T-Cell Response Can Control Productive and Latent Gammaherpesvirus Infection
J. Virol., July 1, 2004; 78(13): 6827 - 6835.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. E. Warrino, W. C. Olson, W. T. Knapp, M. I. Scarrow, L. J. D'Ambrosio-Brennan, R. S. Guido, R. P. Edwards, W. M. Kast, and W. J. Storkus
Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes
Clin. Cancer Res., May 15, 2004; 10(10): 3301 - 3308.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. Bickham, K. Goodman, C. Paludan, S. Nikiforow, M. L. Tsang, R. M. Steinman, and C. Munz
Dendritic Cells Initiate Immune Control of Epstein-Barr Virus Transformation of B Lymphocytes In Vitro
J. Exp. Med., December 1, 2003; 198(11): 1653 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Nikiforow, K. Bottomly, G. Miller, and C. Munz
Cytolytic CD4+-T-Cell Clones Reactive to EBNA1 Inhibit Epstein-Barr Virus-Induced B-Cell Proliferation
J. Virol., November 15, 2003; 77(22): 12088 - 12104.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kobayashi, R. Omiya, B. Sodey, M. Yanai, K. Oikawa, K. Sato, S. Kimura, S. Senju, Y. Nishimura, M. Tateno, et al.
Identification of Naturally Processed Helper T-Cell Epitopes from Prostate-Specific Membrane Antigen Using Peptide-Based in Vitro Stimulation
Clin. Cancer Res., November 1, 2003; 9(14): 5386 - 5393.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2002 by The American Association of Immunologists, Inc. All rights reserved.